BETTER OUTCOME OF HIGH-DOSE CEFTAZIDIME IN HEMATO – ONCOLOGICAL PATIENTS WITH INFECTIONS CAUSED BY EXTENSIVELY DRUG-RESISTANT PSEUDOMONAS AERUGINOSA

Main Article Content

Alzbeta Zavrelova
Jakub Radocha
Pavla Paterova
Pavel Zak
Benjamin Visek
Martin Sima

Keywords

ceftazidime, neutropenia;, XDR P. aeruginosa infection

Abstract

Background: P. aeruginosa sepsis in immunocompromised patients is serious complication of cancer treatment, especially in case of XDR pathogen.


The purpose of the study is to evaluate the efficacy of high-dose ceftazidime in treatment of XDR P. aeruginosa infection and to compare it with the conventionally treated cohort in hemato-oncological patients.


Methods: We identified 27 patients with XDR P. aeruginosa infection during the 2008-2018 period, 16 patients served as a conventionally treated cohort with antipseudomonal beta-lactam antibiotic in standard dose (cohort A), and 11 patients were treated with high-dose ceftazidime (cohort B).  Most of the patients were neutropenic and under active treatment for their cancer in both cohorts.


Results: Mortality and related mortality were statistically significantly better for cohort B compared to cohort A,  it was  18.2% and 9.1% for cohort B and 68.8% and 68.8% for cohort A, respectively. More patients in cohort A needed mechanical ventilation and renal replacement therapy, 75% and 50% for cohort A and 27.3% and 9.9% for cohort B, respectively.  It corresponded well with the worst SOFA in cohort A in comparison to cohort B, 16 versus 7 respectively. Reversible neurotoxicity was seen only in two patients in cohort B.


Conclusion: Ceftazidime in high doses is a very potent ATB for the treatment of XDR P. aeruginosa infections in neutropenic cancer with acceptable toxicity.

Downloads

Download data is not yet available.


Abstract 780
PDF Downloads 861
HTML Downloads 339